Impact of hypoglycemic drugs on the course of COVID-19 in patients with type 2 diabetes mellitus

• Main Authors: Yasmin Ahmed Ali El-Taravi (Author), Emiliya S. Rassadina (Author), Valeriya S. Kuzenkova (Author), Tatiana S. Kokorina (Author), Alina I. Dzarasova (Author), Ella T. Rogava (Author), Irina A. Kuzina (Author), Narine S. Martirosyan (Author), Nina A. Petunina (Author)
• Format: Book
• Published: LLC "MEDIAFORMAT", 2023-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Diabetes mellitus and hyperglycemia are independent risk factors for morbidity, severe course, and adverse outcomes of a nevel coronavirus infection. The article discusses the features of the course of COVID-19 in patients with diabetes. Chronic hyperglycemia is associated with endothelial dysfunction, increased expression of pro-inflammatory cytokines, and a hypercoagulable state that aggravates the course of a viral infection. In turn, COVID-19 is associated with an increased risk of manifestation of diabetes mellitus, the SARS-CoV-2 virus can act as a potential trigger agent. There are still a number of unresolved questions, in particular, whether the virus can cause the manifestation of a special type of diabetes. No less relevant is the issue of optimal hypoglycemic therapy in patients with type 2 diabetes and COVID-19. Hypoglycemic therapy, by influencing various links in the pathogenesis of diabetes mellitus and lowering the level of glycemia, can potentially reduce the risks of complications and severe course of COVID-19 in patients with diabetes mellitus.

Item Description

10.47407/kr2023.4.4.00253
2713-2552